• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Icosavax Inc.

    2/14/24 4:01:16 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICVX alert in real time by email
    SC 13G 1 p24-0799sc13g.htm ICOSAVAX, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Icosavax, Inc.

    (Name of Issuer)
     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    45114M109

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 45114M10913GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Pentwater Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,000,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.9%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

    CUSIP No. 45114M10913GPage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Matthew Halbower

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    3,000,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    3,000,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,000,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.9%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 45114M10913GPage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Icosavax, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1930 Boren Avenue, Suite 1000, Seattle, WA 98101.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i)

    Pentwater Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds (the "Pentwater Funds"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Pentwater Funds; and

     

      (ii) Mr. Matthew Halbower ("Mr. Halbower"), the sole shareholder of Halbower Holdings, Inc., the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Pentwater Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 1001 10th Avenue South, Suite 216, Naples, FL 34102.

     

    Item 2(c). CITIZENSHIP:

     

      The Investment Manager is a Delaware limited partnership.  Mr. Halbower is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, par value $0.0001 per share (the "Common Stock").

     

     

    CUSIP No. 45114M10913GPage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      45114M109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                      

     

    Item 4. OWNERSHIP.

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 50,802,709 shares of Common Stock outstanding as of December 22, 2023, as reported in the Company's Solicitation/Recommendation Statement on Schedule 14D-9 filed with the Securities and Exchange Commission on December 27, 2023.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

     

    CUSIP No. 45114M10913GPage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Pentwater Funds has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 45114M10913GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED:  February 14, 2024  
       
      Pentwater Capital Management LP
       
      By: Halbower Holdings, Inc., its general partner
         
      By: /s/ Matthew Halbower
      Name: Matthew Halbower
      Title: Chief Executive Officer
         
         
      /s/ Matthew Halbower
      Matthew Halbower

     

      

    Get the next $ICVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICVX

    DatePrice TargetRatingAnalyst
    11/17/2023$28.00Buy
    Guggenheim
    1/4/2023$27.00Outperform
    Oppenheimer
    6/29/2022$18.00In-line → Outperform
    Evercore ISI
    3/25/2022$50.00 → $10.00Outperform → In-line
    Evercore ISI
    12/29/2021$50.00Buy
    Jefferies
    8/23/2021$50.00Outperform
    Evercore ISI Group
    8/23/2021$45.70Outperform
    William Blair
    8/23/2021Outperform
    Cowen & Co.
    More analyst ratings

    $ICVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Frazier Life Sciences Adds Industry Veteran and Serial Dealmaker, Adam Simpson, to Company Creation Team

    Simpson has helped build 11 companies that have been acquired or gone public, most recently serving as CEO of Icosavax Frazier Life Sciences (FLS), a longstanding investment firm investing in innovative biopharmaceuticals, today announced the addition of industry veteran Adam Simpson as Venture Partner in its Company Creation team. Over the last 25 years, Simpson has served as a co-founder, executive and/or board member of 11 life sciences companies that have either been acquired or gone public. His broad experience from these roles focuses on team building, advancing novel technologies through clinical proof-of-concept and leading significant fundraising, partnerships and acquisitions. H

    9/19/24 8:00:00 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

    PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics ("CHARM", "The Company"), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine. The newly formed Board is comprised of world-leading experts whose skillsets span 3D deep learning and protein structure prediction, drug discovery and oncology. These individuals have a deep understanding of CHARM and

    3/19/24 10:00:00 AM ET
    $ICVX
    $LYEL
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

    Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ:ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX

    12/12/23 7:00:00 AM ET
    $AZN
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ra Capital Management, L.P.

    4 - Icosavax, Inc. (0001786255) (Issuer)

    2/20/24 8:07:29 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Simpson Adam K. closing all direct ownership in the company (SEC Form 4)

    4 - Icosavax, Inc. (0001786255) (Issuer)

    2/20/24 7:58:17 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Khan Amin

    4 - Icosavax, Inc. (0001786255) (Issuer)

    2/20/24 7:52:01 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    SEC Filings

    View All

    SEC Form 15-12G filed by Icosavax Inc.

    15-12G - Icosavax, Inc. (0001786255) (Filer)

    3/1/24 8:30:10 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-T/A filed by Icosavax Inc. (Amendment)

    SC TO-T/A - Icosavax, Inc. (0001786255) (Subject)

    2/21/24 8:32:03 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Icosavax Inc.

    EFFECT - Icosavax, Inc. (0001786255) (Filer)

    2/21/24 12:15:18 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Icosavax with a new price target

    Guggenheim initiated coverage of Icosavax with a rating of Buy and set a new price target of $28.00

    11/17/23 7:40:10 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Icosavax with a new price target

    Oppenheimer initiated coverage of Icosavax with a rating of Outperform and set a new price target of $27.00

    1/4/23 7:37:57 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Icosavax upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Icosavax from In-line to Outperform and set a new price target of $18.00

    6/29/22 2:31:11 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    Financials

    Live finance-specific insights

    View All

    Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

    - IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + hMPV VLP candidate, in 2H 2022 – - Company to host conference call/webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SEATTLE, June 28, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP

    6/28/22 4:05:00 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Icosavax Inc. (Amendment)

    SC 13D/A - Icosavax, Inc. (0001786255) (Subject)

    2/21/24 4:21:27 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Icosavax Inc. (Amendment)

    SC 13D/A - Icosavax, Inc. (0001786255) (Subject)

    2/21/24 4:17:53 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Icosavax Inc. (Amendment)

    SC 13G/A - Icosavax, Inc. (0001786255) (Subject)

    2/14/24 4:58:16 PM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ICVX
    Leadership Updates

    Live Leadership Updates

    View All

    Icosavax Provides Corporate Update and Anticipated Milestones for 2022

    SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS). Icosavax has exercised its option for a non-exclusive patent license granted by UW and HHS for use of its computationally designed, two component VLP platform in the influenza field, as the company executes on its strategy to

    1/7/22 8:00:00 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Icosavax Appoints Dr. John Shiver to Board of Directors

    SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in the world, Sanofi Pasteur and Merck & Co., Inc. He has guided scientific teams to create novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including RSV, infl

    1/5/22 8:00:00 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

    SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. "Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies," said Adam Simpson, Chief Executive Officer of Icosavax. "I am thrilled to begin working alongside Elizabeth and look forward to her valuable insight as we work to progress our clinical candidates down the development pipeline and continue to grow the compa

    9/10/21 8:00:00 AM ET
    $ICVX
    Biotechnology: Pharmaceutical Preparations
    Health Care